These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31840838)

  • 61. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Clinical, histopathologic, and immunohistochemical analyses.
    Nagatani T; Matsuzaki T; Iemoto G; Kim S; Baba N; Miyamoto H; Nakajima H
    Cancer; 1990 Dec; 66(11):2380-6. PubMed ID: 2245393
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emerging drugs for the treatment of cutaneous T-cell lymphoma.
    Cheng M; Zain J; Rosen ST; Querfeld C
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):45-54. PubMed ID: 35235473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
    Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
    J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
    Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
    J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mogamulizumab: 2 birds, 1 stone.
    Wilcox RA
    Blood; 2015 Mar; 125(12):1847-8. PubMed ID: 25792728
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypersensitivity reaction to β-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab
.
    Yasu T; Imai Y; Ohno N; Uchimaru K; Kurokawa Y; Tojo A
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):807-810. PubMed ID: 28793956
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
    Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
    Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy.
    Jour G; Aung PP; Merrill ED; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Duvic M; Miranda RN; Torres-Cabala CA
    J Dermatol Sci; 2018 Jan; 89(1):88-91. PubMed ID: 29030090
    [No Abstract]   [Full Text] [Related]  

  • 74. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
    Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma.
    Stammler R; Ta VA; Cohen E; Ram-Wolff C; Bozonnat A; Battesti G; Louveau B; Mourah S; Battistella M; Moins-Teisserenc H; de Masson A
    Br J Dermatol; 2024 May; 190(6):920-921. PubMed ID: 38390970
    [No Abstract]   [Full Text] [Related]  

  • 78. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
    Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Blood Adv; 2020 May; 4(10):2180-2191. PubMed ID: 32433748
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
    Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.